Annual report pursuant to Section 13 and 15(d)

Description of Business and Basis of Presentation (Details Narrative)

v3.8.0.1
Description of Business and Basis of Presentation (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Oct. 30, 2017
Oct. 05, 2017
Sep. 21, 2017
Feb. 22, 2017
Feb. 07, 2017
Nov. 02, 2015
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Apr. 18, 2017
Dec. 31, 2015
Reserve stock split, description     1-for-15 reverse stock split effective October 5, 2017   1-for-30 reverse stock split of the Company’s shares of common stock effective on February 22, 2017 1-for-10 reverse stock split          
Common stock conversion description   Every 15 shares of the Company’s then outstanding common stock was combined and automatically converted into one share   As a result of the Reverse Stock Splits, every 30 shares of the Company;s then outstanding common stock was combined and automatically converted into one share   In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive 0.4096 shares of common stock of the Company          
Holders equity percentage               10.00%      
Stockholder's equity             $ 40,613,461 $ 40,613,461 $ 14,885,896 $ 2,500,000 $ 1,193,799
Common stock par value   $ 0.01   $ 0.01     $ 0.01 $ 0.01 $ 0.01    
Common stock shares authorized         500,000,000   500,000,000 500,000,000 500,000,000    
Preferred stock shares authorized         5,000,000   5,000,000 5,000,000      
Working capital deficit             $ 21,500,000 $ 21,500,000      
Indebtedness amount             7,800,000 $ 7,800,000      
Debt maturity date               May 30, 2018      
Proceeds from issuance debentures               $ 15,700,000      
Proceeds from issuance of warrants               15,700,000      
Proceeds from related parties $ 4,300,000             $ 4,765,000 $ 10,000,567    
Proceeds from issuance of convertible preferred stock $ 4,000,000                    
Revenue earned for services             $ 1,800,000        
Medytox Solutions, Inc [Member]                      
Holders equity percentage               90.00%      
Debt maturity date               Aug. 31, 2017